Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 3,925 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HTN Clear all
Completed No phase listed Observational Accepts healthy volunteers

Mechanism of Thrombocytopenia in Infants

NCT00333333
View directory record Official record
Conditions
Thrombocytopenia, Small for Gestational Age (SGA), Preeclampsia
Interventions
Cord blood
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 13, 2008 · Synced Nov 11, 2026, 5:22 AM EST
Completed Not applicable Interventional

Endoscopic Goniotomy for Infantile Glaucoma

NCT00338533
View directory record Official record
Conditions
Glaucoma
Interventions
endoscopic goniotomy
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Week to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Nov 11, 2026, 5:22 AM EST
Terminated Phase 2 Interventional

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04816604
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
GB002 (seralutinib), Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
Gossamer Bio USA, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 11, 2026, 5:22 AM EST
Completed Not applicable Interventional

Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

NCT04452279
View directory record Official record
Conditions
Ocular Surface Disease, Glaucoma, Open-Angle
Interventions
iStent or iStent inject implantation with concomitant cataract surgery
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Nov 11, 2026, 5:22 AM EST
Completed Not applicable Interventional Results available

Cardiovascular Risk Screening and Risk Reduction in Women Vets

NCT02991534
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Hyperlipidemias, Dyslipidemias, Obesity, Diabetes Mellitus, Tobacco Use Disorder, Overweight
Interventions
CV Toolkit Components
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Female only
Enrollment
6,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Sepulveda, California • West Los Angeles, California • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 3 Interventional

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

NCT00200434
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 4 Interventional Results available

Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

NCT01157234
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 3 Interventional

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

NCT00051155
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Nov 11, 2026, 5:22 AM EST
Recruiting Not applicable Interventional

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

NCT07220876
View directory record Official record
Conditions
Open Angle Glaucoma (OAG)
Interventions
VisiPlate Glaucoma Implant
Device
Lead sponsor
Avisi Technologies Inc.
Industry
Eligibility
45 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Glendale, Arizona • Los Angeles, California • Petaluma, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 1Phase 2 Interventional

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

NCT00846989
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983A, Latanoprost
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Artesia, California • Inglewood, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Nov 11, 2026, 5:22 AM EST
Completed Not applicable Interventional Results available

SENSIMED Triggerfish Safety and Tolerability

NCT01319617
View directory record Official record
Conditions
Glaucoma
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Nov 11, 2026, 5:22 AM EST
Enrolling by invitation Not applicable Interventional

MTM2MTG Pilot Ancillary Study

NCT07620808
View directory record Official record
Conditions
Diet, Healthy, HbA1c, Blood Pressure
Interventions
Medically Tailored Groceries
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
20 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 11, 2026, 5:22 AM EST
Active, not recruiting Not applicable Interventional

Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)

NCT03288025
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Insulin Resistance
Interventions
Nutrition and Exercise
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 11, 2026, 5:22 AM EST
Completed No phase listed Observational

Methods for Measuring Insulin Sensitivity

NCT00001625
View directory record Official record
Conditions
Obesity, Hypertension, Diabetes-Mellitus, Non-Insulin Dependent
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Nov 11, 2026, 5:22 AM EST
Not yet recruiting No phase listed Observational

PureSee EDOF Versus ZCB00 Monofocal IOLs in Mild-to-Moderate Glaucoma

NCT07924215
View directory record Official record
Conditions
Primary Open-Angle Glaucoma
Interventions
TECNIS PureSee Intraocular Lens, TECNIS ZCB00 Monofocal Intraocular Lens
Device
Lead sponsor
Mann Eye Institute
Other
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 1 Interventional

Study of ANX007 in Participants With Primary Open-angle Glaucoma

NCT04188015
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
2.5mg ANX007, 5.0mg ANX007, Sham Procedure
Biological · Other
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Newport Beach, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Nov 11, 2026, 5:22 AM EST
Not listed No phase listed Observational

Identification of Heritable CTEPH

NCT03579862
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Blood Draw
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 3 Interventional Results available

FUTURE 3 Study Extension

NCT01338415
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Bosentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
3 Months to 12 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 11, 2026, 5:22 AM EST
Completed Not applicable Interventional

Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure Readings

NCT03323840
View directory record Official record
Conditions
Hypertension
Interventions
Incentivized Care
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 4 Interventional Results available

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT00673790
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Nov 11, 2026, 5:22 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

NCT00817414
View directory record Official record
Conditions
Hypertension
Interventions
LCI699-matching placebo, LCI699
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
10
States / cities
Beverly Hills, California • Buena Park, California • Harbor City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Nov 11, 2026, 5:22 AM EST
Completed Not applicable Interventional

Implementing Digital Health in a Learning Health System

NCT03713333
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Heart Failure, Atrial Fibrillation, Metabolic Syndrome, Genetic Disease
Interventions
Digital Health Device Diagnostics
Diagnostic Test
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Nov 11, 2026, 5:22 AM EST